

## **AAD 19: Psoriasis – Shared Decision Making in the Treatment of Psoriasis**

- **National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes**
- **– Meaningful Measure Area: Care is Personalized and Aligned with Patient’s Goals**

### **2024 COLLECTION TYPE:**

**QCDR MEASURE**

### **MEASURE TYPE:**

Process – High Priority

### **DESCRIPTION:**

Percentage of patients with a diagnosis of psoriasis with a documented shared decision-making discussion that includes the patient’s treatment goals, preferences, and the risks & benefits of treatment options.

High Priority Measure: Yes

Meaningful Measure Area: Care is Personalized and Aligned with Patient’s Goals

Risk-Adjusted: No

Inverse Measure: No

Proportional Measure: Yes

Continuous Variable Measure: No

Ratio Measure: No

Number of performance rates required for measure: 1st Performance Rate

### **INSTRUCTIONS:**

This measure is to be submitted a minimum of once per performance period for all patients with a diagnosis of psoriasis seen during the performance period. This measure may be reported by eligible physicians and allied professionals who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

### **Measure Reporting via Registry**

ICD-10-CM diagnosis codes, CPT codes or HCPCS codes and patient demographics are used to identify patients who are included in the measure’s denominator. The listed numerator options are used to report the numerator of the measure.

The quality-data codes listed do not need to be submitted for registry-based submissions; however, these codes may be submitted for those registries that utilize claims data.

### **DENOMINATOR:**

All patients regardless of age with a diagnosis of psoriasis.

**DENOMINATOR NOTE:** \*Signifies that this CPT Category I code is a non-covered service under the Medicare Part B Physician Fee Schedule (PFS). These non-covered services should be counted in the denominator population for MIPS CQMs.

### **Denominator Criteria (Eligible Cases):**

All patients, regardless of age

### **AND**

**Diagnosis for Psoriasis (ICD-10-CM):** L40.0, L40.1, L40.2, L40.3, L40.4, L40.8, L40.9

### **AND**

**Patient encounter during reporting period (CPT and/or CPT with telehealth modifier):** 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99241\*, 99242\*, 99243\*, 99244\*, 99245\*, GQ, 95, POS 02

**NUMERATOR:**

Patients or parent/legal guardians of patients with documented shared decision-making discussion of treatment goals, preferences, and risks & benefits of treatment options in the medical record.

**Definition(s):**

Shared Decision-Making: A formal process of consensus building between health care professionals and patients to select treatment plans based on the best medical evidence and the patient's values.[1]

Documentation in the medical record should include discussion of the patient's treatment goals, preferences and the risks and benefits of treatment options. Example language could include: "Shared decision-making was used to determine the treatment plan with the patient/caregiver. The risks and benefits of treatment options were discussed and aligned with the patient's/caregiver's goals and preferences."

**Numerator Instructions:**

The shared decision-making discussion between patients and physicians and allied professionals should focus on identifying the most effective and appropriate treatment plan that aligns with the needs, goals, and preferences of the patient.

**Numerator Options:**

**Performance Met:** Documentation in the medical record of a shared decision-making discussion including the patient's treatment goals, preferences and the risks & benefits of treatment options.

**OR**

**Performance not Met:** No documentation in the medical record of a shared decision-making discussion including the patient's treatment goals, preferences and the risks & benefits of treatment options.

**COPYRIGHT:**

©American Academy of Dermatology/Association. All rights reserved.

The American Academy of Dermatology and the American Academy of Dermatology Association (collectively AAD/A) own all right, title, and interest in this quality measure. This quality measure is provided solely for the benefit of AAD/A and its members for the purposes specified herein and for other AAD/A purposes. It may not be used by other parties except with prior written approval of the AAD/A.